Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Ciclesonide
Drug ID BADD_D00460
Description Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. It is marketed under the brand name Alvesco.
Indications and Usage For the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.
Marketing Status approved; investigational
ATC Code R01AD13; R03BA08
DrugBank ID DB01410
KEGG ID D01703
MeSH ID C120481
PubChem ID 6918155
TTD Drug ID D0K7HU
NDC Product Code 70515-711; 53104-7633; 70515-712; 70515-701; 64918-1900; 24002-0016; 64918-1112; 70515-737
UNII S59502J185
Synonyms ciclesonide | (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | Alvesco | Omnaris
Chemical Information
Molecular Formula C32H44O7
CAS Registry Number 126544-47-6
SMILES CC(C)C(=O)OCC(=O)C12C(CC3C1(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)OC(O2)C6CCCCC6
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Sinus headache17.14.01.002; 22.12.03.022--
Sinusitis11.01.13.005; 22.07.03.007--
Skin lesion23.03.03.010---
Sneezing22.12.03.024--
Somnolence17.02.04.006; 19.02.05.0030.000834%
Sputum discoloured22.02.03.0100.000947%-
Stress19.06.02.004---
Swelling08.01.03.015---
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.018---
Swollen tongue07.14.02.003; 10.01.05.015; 23.04.01.014---
Tachycardia02.03.02.0070.000379%-
Throat irritation07.05.05.037; 22.12.03.0290.000379%-
Tonsillitis11.01.13.006; 22.07.03.008---
Type I hypersensitivity10.01.03.006---
Ulcer08.03.06.001---
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.0010.000379%
Viral upper respiratory tract infection11.05.04.007; 22.07.02.004---
Vision blurred06.02.06.007; 17.17.01.0100.001023%
Visual impairment06.02.10.013---
Weight increased13.15.01.006--
Wheezing22.03.01.0090.001971%
White blood cell count increased13.01.06.013---
Seasonal allergy06.04.01.013; 10.01.04.001; 22.04.04.008---
Peripheral swelling02.05.04.015; 08.01.03.053---
Osteopenia14.04.04.004; 15.02.03.003---
General physical health deterioration08.01.03.018---
Balance disorder08.01.03.081; 17.02.02.007---
Muscle strain12.01.07.004; 15.05.07.002---
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages